Menu

Wolfson Institute of Preventive Medicine

Search - ZOO
Search - K2
Search - Categories
Search - Contacts
Search - Content
Search - Newsfeeds
Search - Weblinks

Publications

We maintain an archive of past and current publications which can be searched by clicking on the links to the left or by using the drop down menus at the top of this page to search by author name, journal name or year of publication.

Alternatively you can use the search bar to look up a key word.

Our most recent publications are listed below.

Ivana Sestak Publications

Authors

Publication Summary

Journal

Years

Heindl A, Sestak I, Naidoo K, Cuzick J, Dowsett M, Yuan Y Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer.. vol.110, (2) .
10.1093/jnci/djx137
J Natl Cancer Inst2018
Sestak I, Smith SG, Howell A, Forbes JF, Cuzick J Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.. vol., () .
10.1093/annonc/mdx713
Ann Oncol2017
Bartlett JMS, Ahmed I, Regan MM, Sestak I, Mallon EA, Dell'Orto P, Thürlimann B, Seynaeve C, Putter H, Van de Velde CJH, Brookes CL, Forbes JF, Viale G, Cuzick J, Dowsett M, Rea DW, Translational Aromatase Inhibitor Overview Group (Trans-AIOG) HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.. vol.79, () 129 - 138.
10.1016/j.ejca.2017.03.033
Eur J Cancer2017
Smith SG, Sestak I, Howell A, Forbes J, Cuzick J Participant-reported symptoms and their impact on long-term adherence in the International Breast Cancer Intervention Study (IBIS-1). vol.35, (23) .
10.1200/JCO.2016.71.7439
Journal of Clinical Oncology2017
Sestak I Identifying Biomarkers to Select Patients with Early Breast Cancer Suitable for Extended Adjuvant Endocrine Therapy. vol.12, (3) 146 - 151.
10.1159/000477795
BREAST CARE2017
CUZICK JM, Bartlett J, Ikhlaaq A, Regan MM, Sestak I, Mallon EA, Dell'Orto P, Thürlimannh B, Seynaevei C, Putter H, Van de Velde C, Brookes CL, Forbes JF, Viale G, Dowsett M, Rea D HER2 status predicts for upfront AI benefit: a TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. vol., () .
10.1016/j.ejca.2017.03.033
European Journal of Cancer2017
Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Ferree S, Sgroi D, Schnabel C, Baehner R, Mallon E, Dowsett M Comprehensive comparison of prognostic signatures for breast cancer in TransATAC. vol.77, () .
10.1158/1538-7445.SABCS16-S6-05
CANCER RESEARCH2017
Cuzick J, Sestak I, Bianco A, Strobbe L, Bergh J, Hanusch C, Neven P, Dowsett M, Forbes JF, Buzdar A, Smith R, Howell A Long-term comparison of anastrozole versus tamoxifen: Results from LATTE/ATAC. vol.77, () .
10.1158/1538-7445.SABCS16-P2-09-03
CANCER RESEARCH2017
Smith SG, Sestak I, Forbes J, Howell A, Cuzick JJ Menopausal symptoms as predictors of long-term adherence in the International breast cancer intervention study (IBIS-1). vol.77, () .
10.1158/1538-7445.SABCS16-S5-03
CANCER RESEARCH2017
CUZICK J, BRENTNALL AR, Segal C, Byers H, Reuter C, Detre S, Lopez-Knowles E, Sestak I, Howell A, Powles TJ, Newman WG, Dowsett M Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials. vol.35, (7) 743 - 750.
10.1200/jco.2016.69.8944
Journal of Clinical Oncology2016
Guerrieri-Gonzaga A, Sestak I, Lazzeroni M, Serrano D, Rotmensz N, Cazzaniga M, Varricchio C, Pruneri G, Leonardi MC, Orecchia R, Galimberti V, Bonanni B, DeCensi A Benefit of low dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS. vol.139, (9) 2127 - 2134.
10.1002/ijc.30254
International Journal of Cancer2016
Buus R, Sestak I, Kronenwett R, Denkert C, Dubsky P, Krappmann K, Scheer M, Petry C, Cuzick J, Dowsett M Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.. vol.108, (11) .
10.1093/jnci/djw149
Journal of the National Cancer Institute2016
Lakhanpal R, Sestak I, Shadbolt B, Bennett GM, Brown M, Phillips T, Zhang Y, Bullman A, Rezo A IHC4 score plus clinical treatment score predicts locoregional recurrence in early breast cancer. vol.29, () 147 - 152.
10.1016/j.breast.2016.06.019
The Breast2016
Sestak I, Zhang Y, Schroeder BE, Schnabel CA, Dowsett M, Cuzick J, Sgroi D Cross Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in women with hormone receptor positive lymph-node negative early stage breast cancer. vol.22, (18) .
10.1158/1078-0432.CCR-16-0155
Clinical Cancer Research2016
Sestak I, Dowsett M, Ferree S, Baehner FL, Cuzick J Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors. vol.159, (1) .
10.1007/s10549-016-3868-y
Breast Cancer Research and Treatment2016
Guerrieri-Gonzaga A, Sestak I, Lazzeroni M, Serrano D, Rotmensz N, Cazzaniga M, Varricchio C, Thorat MA, Pruneri G, Leonardi MC, Galimberti V, Bonanni B, DeCensi A Benefit of low-dose tamoxifen in a large, single-institution cohort of high-risk ER-positive DCIS. vol.76, () .
10.1158/1538-7445.AM2016-1788
CANCER RESEARCH2016
Sestak I, Yeo B, Dodson A, Dowsett M, Cuzick JM Improved use of clinical variables for prognosis of distant recurrence in patients with ER plus breast cancer treated with 5 years endocrine therapy.. vol.34, (15) .
10.1200/JCO.2016.34.15_suppl.566
JOURNAL OF CLINICAL ONCOLOGY2016
Smith SG, Sestak I, Forster A, Partridge A, Side L, Wolf MS, Horne R, Wardle J, Cuzick J Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis.. vol.27, (4) 575 - 590.
10.1093/annonc/mdv590
Ann Oncol2016
Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J, IBIS-II investigators Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.. vol.387, (10021) 866 - 873.
10.1016/S0140-6736(15)01129-0
Lancet2016
Cuzick J, Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones LJ, Ellis I Anastrozole versus tamoxifen for the prevention of loco-regional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ (IBIS-II DCIS). vol.76, () .
10.1158/1538-7445.SABCS15-S6-03
CANCER RESEARCH2016
Dowsett M, Sestak I, Buus R, Kronenwett R, Denkert C, Krappmann K, Scheer M, Petry C, Dubsky P, Cuzick J EndoPredict (EPclin) score for estimating residual distant recurrence (DR) risk in ER+/HER2-breast cancer (br ca) patients treated with 5 years adjuvant endocrine therapy alone: Validation and comparison with the oncotype DX recurrence score (RS). vol.76, () .
10.1158/1538-7445.SABCS15-S3-01
CANCER RESEARCH2016
Smith SG, Sestak I, Forster A, Partridge A, Side L, Horne R, Wardle J, Cuzick J Factors affecting uptake and adherence to breast cancer chemoprevention: A systematic review and meta-analysis. vol.76, () .
10.1158/1538-7445.SABCS15-PD1-08
CANCER RESEARCH2016
Bartlett JMS, Ahmed I, Regan MM, Sestak I, Mallon EA, Dell'Orto P, Thurlimann BJK, Seynaeve C, Putter H, Brookes CL, Forbes JF, Colleoni MA, Bayani J, van de Velde CJH, Viale G, Cuzick J, Dowsett M, Rea DW, Inhibitor TA HER2 status as predictive marker for Al vs Tam benefit: A TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. vol.76, () .
10.1158/1538-7445.SABCS15-S4-06
CANCER RESEARCH2016
Sestak I, Zhang Y, Schroeder B, Dowsett M, Sgroi D, Cuzick J, Schnabel CA Integration of tumor size and grade with the breast cancer index (BCI) for prediction of distant recurrence in hormone receptor-positive breast cancer with 1-3 positive lymph nodes. vol.76, () .CANCER RESEARCH2016
Sestak I, Zhang Y, Schroeder B, Dowsett M, Sgroi D, Cuzick J, Schnabel CA Integration of tumor size and grade with the breast cancer index (BCl) for prediction of distant recurrence in hormone receptor-positive breast cancer with 1-3 positive lymph nodes. vol.76, () .CANCER RESEARCH2016
Zhang Y, Sestak I, Schroeder BE, Dowsett M, Cuzick J, Schnabel CA, Sgroi DC Prognostic impact of the combined risk groups by breast cancer index and HOXB13/IL17BR ratio in hormonal receptor positive, node negative breast cancer: A TransATAC study. vol.76, () .CANCER RESEARCH2016
Spagnolo F, Sestak I, Howell A, Forbes JF, Cuzick J Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial. vol.34, (2) 139 - 143.
10.1200/JCO.2015.63.4972
Journal of Clinical Oncology2016
Cuzick J, Sestak I, Thorat MA Impact of preventive therapy on the risk of breast cancer among women with benign breast disease.. vol.24 Suppl 2, () S51 - S55.
10.1016/j.breast.2015.07.013
Breast2015
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.. vol.386, (10001) 1341 - 1352.
10.1016/S0140-6736(15)61074-1
Lancet2015
Wallden B, Storhoff J, Nielsen T, Dowidar N, Schaper C, Ferree S, Liu S, Leung S, Geiss G, Snider J, Vickery T, Davies SR, Mardis ER, Gnant M, Sestak I, Ellis MJ, Perou CM, Bernard PS, Parker JS Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.. vol.8, () 54.
10.1186/s12920-015-0129-6
BMC Med Genomics2015
Gnant M, Sestak I, Filipits M, Dowsett M, Balic M, Lopez-Knowles E, Greil R, Dubsky P, Stoeger H, Rudas M, Jakesz R, Ferree S, Cowens JW, Nielsen T, Schaper C, Fesl C, Cuzick J Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.. vol.26, (8) 1685 - 1691.
10.1093/annonc/mdv215
Ann Oncol2015
Dowsett M, Sestak I, Buus R, Lopez-Knowles E, Mallon E, Howell A, Forbes JF, Buzdar A, Cuzick J Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer.. vol.21, (12) 2763 - 2770.
10.1158/1078-0432.CCR-14-2842
Clin Cancer Res2015
Mote PA, Gompel A, Howe C, Hilton HN, Sestak I, Cuzick J, Dowsett M, Hugol D, Forgez P, Byth K, Graham JD, Clarke CL Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial.. vol.151, (2) 309 - 318.
10.1007/s10549-015-3397-0
Breast Cancer Res Treat2015
Zhang Y, Sestak I, Cuzick JM, Dowsett M, Schnabel CA, Sgroi D Correlation of Breast Cancer Index HOXB13/IL17BR (H/I), ER, PR and HER2 and prediction of relative endocrine benefit from tamoxifen and anastrozole in HR plus breast cancer: A TransATAC study.. vol.33, (15) .JOURNAL OF CLINICAL ONCOLOGY2015
Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF 16 year long-term follow-up of the IBIS-I breast cancer prevention trial. vol.75, () .
10.1158/1538-7445.SABCS14-S3-07
CANCER RESEARCH2015
Sestak I, Zhang Y, Schroeder BE, Goss PE, Dowsett M, Sgroi DC, Schnabel CA, Cuzick J Integration of breast cancer index (BCI) with clinicopathological factors for prediction of distant recurrence in ER plus breast cancer. vol.75, () .
10.1158/1538-7445.SABCS14-P4-11-19
CANCER RESEARCH2015
Hiscox S, Smith C, Nicholson RI, Gee J, Harris A, Bliss J, Kalaizak E, Sestak I, Dowsett M, Cuzick J, Ellis I, Barrett-Lee P Nuclear beta-catenin negativity predicts for late relapse in ER plus , tamoxifen-treated breast cancer. vol.75, () .
10.1158/1538-7445.SABCS14-P3-06-01
CANCER RESEARCH2015
Sestak I, Howell A, Forbes JF, Neven P, Cuzick J Timing, severity and risk factors for arthralgia in the IBIS-II trial: A retrospective and exploratory analysis. vol.75, () .
10.1158/1538-7445.SABCS14-PD4-1
CANCER RESEARCH2015
Sestak I, Cuzick J, Dowsett M, Lopez-Knowles E, Filipits M, Dubsky P, Cowens JW, Ferree S, Schaper C, Fesl C, Gnant M Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score.. vol.33, (8) 916 - 922.
10.1200/JCO.2014.55.6894
Journal of Clinical Oncology2015
Sestak I, Cuzick J Update on breast cancer risk prediction and prevention.. vol.27, (1) 92 - 97.
10.1097/GCO.0000000000000153
Curr Opin Obstet Gynecol2015
Sestak I, Cuzick J Markers for the identification of late breast cancer recurrence.. vol.17, () 10.
10.1186/s13058-015-0516-0
Breast Cancer Res2015
Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF, IBIS-I Investigators Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.. vol.16, (1) 67 - 75.
10.1016/S1470-2045(14)71171-4
Lancet Oncol2015
Sestak I, Singh S, Cuzick J, Blake GM, Patel R, Gossiel F, Coleman R, Dowsett M, Forbes JF, Howell A, Eastell R Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. vol.15, (13) 1460 - 1468.
10.1016/S1470-2045(14)71035-6
Lancet Oncology2014
Sestak I, Singh S, Cuzick J Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, doubleblind, randomised, placebo-controlled trial (vol 15, pg 1464, 2014). vol.15, (13) E587 - E587.LANCET ONCOLOGY2014
Sestak I, Zhang Y, Schnabel CA, Schroeder B, Ander ME, Goss PE, Cuzick JM, Dowsett M, Sgroi D Clinical impact of differential risk stratification by breast cancer index (BCI) versus recurrence score (RS) in HR plus early-stage breast cancer: A TransATAC study.. vol.32, (15) .JOURNAL OF CLINICAL ONCOLOGY2014
Cuzick JM, Brentnall A, Segal C, Sestak I, Kealy R, Howell A, Powles TJ, Orr N, Newman WG, Dowsett M Use of a SNP panel to refine risk estimates in women at high risk of breast cancer: Results from two randomized tamoxifen prevention trials.. vol.32, (15) .JOURNAL OF CLINICAL ONCOLOGY2014
Eastell R, Sestak I, Gossiel F, Patel R, Blake G, Coleman R, Howell A, Dowsett M, Forbes JF, Singh S, Cuzick J EFFECT OF AROMATASE INHIBITION ON BONE DENSITY AND BONE TURNOVER IN HEALTHY POSTMENOPAUSAL WOMEN: RESULTS OF THE INTERNATIONAL BREAST CANCER INTERVENTION STUDY II (IBIS-II). vol.25, () S281 - S281.OSTEOPOROSIS INTERNATIONAL2014
Cuzick J, Sestak I, Forbes JF, Investigators IBIS-II Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial (vol 383, pg 1041, 2014). vol.383, (9922) 1040 - 1040.LANCET2014
Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A, IBIS-II investigators Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.. vol.383, (9922) 1041 - 1048.
10.1016/S0140-6736(13)62292-8
Lancet2014
Dowsett M, Sestak I, Buus R, Lopez-Knowles E, Cuzick J Oestrogen module of 21-gene recurrence score predicts increased late recurrence for ER+HER2-breast cancer. vol.50, () S105 - S106.EUROPEAN JOURNAL OF CANCER2014
Sestak I, Singh S, Cuzick J, Blake G, Patel R, Coleman R, Dowsett M, Forbes JF, Howell A, Eastell R Risedronate Prevents Anastrozole-Induced Bone Loss In The IBIS-II Prevention Trial.. vol.29, () S110 - S110.JOURNAL OF BONE AND MINERAL RESEARCH2014
Allen MD, Thomas GJ, Clark S, Dawoud MM, Vallath S, Payne SJ, Gomm JJ, Dreger SA, Dickinson S, Edwards DR, Pennington CJ, Sestak I, Cuzick J, Marshall JF, Hart IR, Jones JL Altered microenvironment promotes progression of preinvasive breast cancer: myoepithelial expression of αvβ6 integrin in DCIS identifies high-risk patients and predicts recurrence.. vol.20, (2) 344 - 357.
10.1158/1078-0432.CCR-13-1504
Clin Cancer Res2014
Sestak I Preventative therapies for healthy women at high risk of breast cancer.. vol.6, () 423 - 430.
10.2147/CMAR.S55219
Cancer Manag Res2014
Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A Breast cancer prevention using anastrozole in postmenopausal women at high risk. vol.73, () .
10.1158/0008-5472.SABCS13S3-01
CANCER RESEARCH2013
Sestak I, Cuzick J, Dowsett M, Filipits M, Dubsky P, Cowens W, Ferree S, Schaper C, Fesl C, Gnant M Prediction of late distant recurrence after 5 years of endocrine treatment: A combined analysis of 2485 patients from the ABCSG-8 and transATAC studies using the PAM50 risk of recurrence (ROR) score. vol.73, () .
10.1158/0008-5472.SABCS13-S6-04
CANCER RESEARCH2013
Sestak I, Dowsett M, Zabaglo L, Lopez-Knowles E, Ferree S, Cowens JW, Cuzick J Factors predicting late recurrence for estrogen receptor-positive breast cancer.. vol.105, (19) 1504 - 1511.
10.1093/jnci/djt244
J Natl Cancer Inst2013
Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, Erlander MG, Dunbier A, Sidhu K, Lopez-Knowles E, Goss PE, Dowsett M Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.. vol.14, (11) 1067 - 1076.
10.1016/S1470-2045(13)70387-5
Lancet Oncol2013
Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW, Ferree S, Storhoff J, Schaper C, Cuzick J Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.. vol.31, (22) 2783 - 2790.
10.1200/JCO.2012.46.1558
J Clin Oncol2013
Afentakis M, Dowsett M, Sestak I, Salter J, Howell T, Buzdar A, Forbes J, Cuzick J Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study.. vol.140, (2) 253 - 262.
10.1007/s10549-013-2628-5
Breast Cancer Res Treat2013
Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, Forbes JF, Ford L, LaCroix AZ, Mershon J, Mitlak BH, Powles T, Veronesi U, Vogel V, Wickerham DL, SERM Chemoprevention of Breast Cancer Overview Group Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.. vol.381, (9880) 1827 - 1834.
10.1016/S0140-6736(13)60140-3
Lancet2013
Pugliano L, Zardavas D, Paesmans M, Sestak I, Gelber RD, Cuzick JM, Dowsett M, Awada A, Piccart-Gebhart MJ, De Azambuja E A meta-analysis of endocrine therapy trials in early breast cancer (BC) evaluating the impact of obesity: Are aromatase inhibitors (AIs) optimal therapy in obese ER plus BC?. vol.31, (15) .JOURNAL OF CLINICAL ONCOLOGY2013
Gnant M, Dowsett M, Filipits M, Lopez-Knowles E, Greil R, Balic M, Cowens JW, Nielsen TO, Shaper C, Sestak I, Fesl C, Cuzick JM, Canc ABC Identifying clinically relevant prognostic subgroups in node-positive postmenopausal HR plus early breast cancer patients treated with endocrine therapy: A combined analysis of 2,485 patients from ABCSG-8 and ATAC using the PAM50 risk of recurrence (ROR) score and intrinsic subtype. vol.31, (15) .JOURNAL OF CLINICAL ONCOLOGY2013
Cummins NM, Jakeman PM, Sestak I, Murphy N, Carroll P The effect of behavioural risk factors on osteoporosis in Irish women. vol.182, (1) 97 - 105.
10.1007/s11845-012-0840-7
IRISH JOURNAL OF MEDICAL SCIENCE2013
Eastell R, Sestak I, Gossiel F, Patel R, Blake G, Coleman R, Howell A, Dowsett M, Forbes J, Singh S, Cuzick J Effect of Aromatase Inhibition on Bone Density and Bone Turnover in Healthy Postmenopausal Women: Results of the International Breast cancer Intervention Study II (IBIS-II). vol.28, () .JOURNAL OF BONE AND MINERAL RESEARCH2013
Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Erlander MG, Goss PE, Dowsett M Comparative Performance of Breast Cancer Index (BCI) vs. Oncotype Dx and IHC4 in the Prediction of Late Recurrence in Hormonal Receptor-Positive Lymph Node-Negative Breast Cancer Patients: A TransATAC Study. vol.72, () .
10.1158/0008-5472.SABCS12-S1-9
CANCER RESEARCH2012
Sgroi DC, Sestak I, Zhang Y, Erlander MG, Schnabel CA, Goss PE, Cuzick J, Dowsett M Evaluation of Prognostic and Predictive Performance of Breast Cancer Index and Its Components in Hormonal Receptor-Positive Breast Cancer Patients: A TransATAC Study. vol.72, () .
10.1158/0008-5472.SABCS12-P2-10-15
CANCER RESEARCH2012
Sestak I, Cuzick J Preventive therapy for breast cancer.. vol.14, (6) 568 - 573.
10.1007/s11912-012-0273-5
Curr Oncol Rep2012
Rae JM, Hayes DF, Cuzick J, Sestak I, Dowsett M CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients (vol 104, pg 452, 2012). vol.104, (22) 1772 - 1772.
10.1093/jnci/djs443
JOURNAL OF THE NATIONAL CANCER INSTITUTE2012
Cuzick J, Sestak I, Ferree S, Cowens JW, Dowsett M PREDICTION OF LATE BREAST CANCER RECURRENCE BY THE ROR (PAM50) SCORE IN POSTMENOPAUSAL WOMEN IN THE TRANSATAC COHORT. vol.23, () 75 - 76.ANNALS OF ONCOLOGY2012
Dixon JM, Sestak I, Cuzick J ABC of Breast Diseases. vol., () .2012
Rae JM, Hayes DF, Cuzick J, Sestak I, Dowsett M Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial Response. vol.104, (16) 1267 - 1268.
10.1093/jnci/djs302
JOURNAL OF THE NATIONAL CANCER INSTITUTE2012
Sestak I, Kealy R, Nikoloff M, Fontecha M, Forbes JF, Howell A, Cuzick J Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial.. vol.107, (2) 230 - 233.
10.1038/bjc.2012.278
Br J Cancer2012
Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick J Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer.. vol.134, (2) 727 - 734.
10.1007/s10549-012-2085-6
Breast Cancer Res Treat2012
Iqbal J, Ginsburg OM, Wijeratne TD, Howell A, Evans G, Sestak I, Narod SA Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: A systematic review. vol.38, (4) 318 - 328.
10.1016/j.ctrv.2011.06.009
CANCER TREATMENT REVIEWS2012
Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M, ATAC trialists CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.. vol.104, (6) 452 - 460.
10.1093/jnci/djs126
J Natl Cancer Inst2012
Pinhel I, Hills M, Drury S, Salter J, Sumo G, A'Hern R, Bliss JM, Sestak I, Cuzick J, Barrett-Lee P, Harris A, Dowsett M, NCRI Adjuvant Breast Cancer Trial Management Group ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer.. vol.14, (2) R46.
10.1186/bcr3145
Breast Cancer Res2012
Rae JM, Sestak I, Henry NL, Drury S, Hayes DF, Thibert JN, Lopez-Knowles E, Salter J, Pineda S, Cuzick J, Dowsett M Correlation between Gene Variants in CYP19 (Aromatase) and TCL1A with Disease and Tolerability Endpoints in the ATAC Trial.. vol.71, () .
10.1158/0008-5472.SABCS11-P1-06-02
CANCER RESEARCH2011
Sestak I, Cuzick J, Dowsett M, Salter J, Quinn E, Zabaglo L, Howell A, Buzdar A, Forbes J Prediction of Residual Risk of Recurrence after 5 Years of Follow-Up by Clinicopathologic Variables and 4 IHC Markers: A TransATAC Study.. vol.71, () .
10.1158/0008-5472.SABCS11-P2-12-09
CANCER RESEARCH2011
Ring A, Sestak I, Baum M, Howell A, Buzdar A, Dowsett M, Forbes JF, Cuzick J Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial.. vol.29, (32) 4266 - 4272.
10.1200/JCO.2011.35.5545
J Clin Oncol2011
Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick JM Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with breast cancer or at high risk of developing it. vol.29, (27) .JOURNAL OF CLINICAL ONCOLOGY2011
Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick JM Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with breast cancer or at high risk of developing it.. vol.29, (27_suppl) 165.J Clin Oncol2011
Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, for the ATAC/LATTE investigators 10-year analysis of the ATAC trial: wrong conclusion? - Authors' reply.. vol.12, (3) 217.
10.1016/S1470-2045(11)70050-X
Lancet Oncol2011
Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, ATAC LATTE Investigators 10-year analysis of the ATAC trial: wrong conclusion? Reply. vol.12, (3) 217 - 217.
10.1016/S1470-2045(11)70050-X
LANCET ONCOL2011
Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS, George WD Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.. vol.12, (1) 21 - 29.
10.1016/S1470-2045(10)70266-7
Lancet Oncol2011
Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, ATAC LATTE Investigators Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. vol.11, (12) 1135 - 1141.
10.1016/S1470.2045(10)70257.6
LANCET ONCOL2010
Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, ATAC/LATTE investigators Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.. vol.11, (12) 1135 - 1141.
10.1016/S1470-2045(10)70257-6
Lancet Oncol2010
Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.. vol.28, (21) 3411 - 3415.
10.1200/JCO.2009.27.2021
J Clin Oncol2010
Cuzick J, Sestak I, Pinder SE, Ellis IO, Hackshaw A, Bundred NJ, Forbes JF, Bishop H, Fentiman IS, George WD Beneficial Effect of Tamoxifen for Women with DCIS: Long-Term Results front the UK/ANZ DCIS Trial in Women with Locally Excised DCIS. vol.69, (24) 493S - 493S.CANCER RESEARCH2009
Sestak I, Distler W, Forbes JF, Howell A, Cuzick J Effect of Body Mass Index on Recurrence in Hormone Receptor Positive Early Breast Cancer - A Retrospective Exploratory Analysis from the ATAC Trial. vol.69, (24) 553S - 553S.CANCER RESEARCH2009
Sestak I, Sapunar F, Cuzick J Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial.. vol.27, (30) 4961 - 4965.
10.1200/JCO.2009.22.0236
J Clin Oncol2009
Sestak I, Cuzick J Characteristics of carpal-tunnel syndrome in the ATAC trial.. vol.69, (2) 326S - 326S.CANCER RESEARCH2009
Cuzick J, Sestak I, Cella D, Fallowfield L, ATAC Trialists' Group Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.. vol.9, (12) 1143 - 1148.
10.1016/S1470-2045(08)70259-6
Lancet Oncol2008
Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR, Buzdar AU, ATAC Trialists' Group Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.. vol.9, (9) 866 - 872.
10.1016/S1470-2045(08)70182-7
Lancet Oncol2008
SESTAK I Breast Cancer Chemoprevention: A Risk-benefit Profile for Tamoxifen and Anastrozole. vol., () .2008
Sestak I, Forbes JF, Edwards R, Howell A, Cuzick J Timing and severity of prominent side effects of anastrozole and tamoxifen. vol.6, (7) 71 - 71.
10.1016/S1359-6349(08)70389-6
EJC SUPPLEMENTS2008
Sestak I, ATAC Trialists Grp Risk factors for joint symptoms in the ATAC trial. vol.106, () S108 - S108.BREAST CANCER RESEARCH AND TREATMENT2007
Sestak I, Edwards R, Howell A, Cuzick J Effect of tamoxifen on serum lipid levels in women at increased risk of breast cancer. vol.5, (3) 31 - 31.
10.1016/S1359-6349(07)71791-3
EJC SUPPLEMENTS2007
Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, International Breast Cancer Intervention Study I Investigators Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.. vol.99, (4) 272 - 282.
10.1093/jnci/djk049
J Natl Cancer Inst2007
Sestk I, Edwards R, Howell A, Cuzick J Comparison of side-effect profiles during active treatment versus follow-up in the International Breast Cancer Intervention Study I tamoxifen prevention trial. vol.9, (1) .
10.1186/bcr1723
BREAST CANCER RESEARCH2007
Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.. vol.24, (24) 3991 - 3996.
10.1200/JCO.2005.04.3745
J Clin Oncol2006
Sestak I, Forbes J, Roseann K, Edwards R, Howell A, Cuzick J Comparison of side-effect profiles during active treatment versus follow-up in the IBIS-1 tamoxifen prevention study.. vol.100, () S55 - S55.BREAST CANCER RESEARCH AND TREATMENT2006
Sestak I, Kealy R, Edwards R, Cuzick J The influence of hormone replacement therapy (HRT) on tamoxifen induced vasomotor symptoms.. vol.94, () S11 - S12.BREAST CANCER RESEARCH AND TREATMENT2005
BRENTNALL AR, Cuzick J, Byers H, Segal C, Reuter C, Detre S, Sestak I, Howell A, Powles TJ, Newman WG, Dowsett M Relationship of ZNF423 and CTSO with breast cancer risk in two randomized tamoxifen-prevention trials. vol., () .
10.1007/s10549-016-3885-x
Breast Cancer Research and Treatment
RING AE, SESTAK I, BAUM M, HOWELL A, BUZDAR A, DOWSETT M, FORBES JF, CUZICK J The Influences of Co-Morbidities and Age on Risk of Death without Recurrence: A Retrospective Analysis of the ATAC Trial. vol., () .
10.1158/0008-5472.SABCS10-P5-13-03
Return to top